Search PubMed⌕ Search

Biomedical subjects

J Traeger

Publications and source records attributed to J Traeger.

At least 163 records · Page 9Linked to original sources
PubMed1978

Thoracic duct drainage and antilymphocyte globulin for renal transplantation in man.

Thoracic duct drainage resulting in a lymphocyte depletion of more than 20 x 10(9) cells was performed during the three months prior to transplantation in 37 patients. Results obtained in this group of patients were compared to those in transplant recipients similarly treated, over the same period, but not subjected to thoracic duct drainage. Both groups received comparable doses of antilymphocyte globulins, azathioprine and corticosteroids. No clear-cut difference in transplantation outcome was found when recipients of kidneys from related living donors (whether HLA identical or HLA haploidentical) were considered. By contrast, an improved transplant survival and a decreased incidence of rejection crises were observed in recipients of kidneys from cadaver donors when a thoracic duct drainage was performed prior to transplantation. The immunosuppressive effect of thoracic duct drainage, probably enhanced by antilymphocyte globulin treatment, is therefore a valuable adjunct to more conventional methods of pretreating human cadaveric transplant recipients.

Antilymphocyte Serum↗
PubMed1978

[The use of simultaneous angiography to determine the signification of vascular images in renal scintiscans with technetium (author's transl)].

Combined angiography and renal scintiscans were used by the authors in an attempt to determine the signification of the images and vascular tracings obtained after intravenous injection of technetium (99mTc). They conclude that the scintiscan images are essentially the reflection of cortical vascularization and that its duration, as determined by the scintiscan, is roughly equal to the mean transit time of the indicator employed (Tc). Arterial stenosis cannot be demonstrated by scintiscans using technetium.

Adolescent↗
PubMed1978

[Alteration of beta2-microglobulin metabolism in terminal chronic renal insufficiency (author's transl)].

In 63 patients with chronic renal insufficiency treated with intermittent dialysis plasma beta2m concentrations were shown to be stable and increased 8 to 60 times over normal values. The excretion of beta2m is achieved either through residual diuresis (up to 150 mg/24 h) or by filtration through high permeability membranes of the dialyser. In the absence of extra-renal catabolism of beta2m it is suggested that the rate of beta2m synthesis differs markedly among patients. beta2m it self does not to seem to contribute to the toxic manifestations of chronic renal insufficiency.

Beta-Globulins↗
PubMed1977

[Anticomplementary activity of a polyanion: polyanion: pentosan-poly-sulfoester. I. "In vitro" study and "in vivo" trial in human glomerulonephritis (author's transl)].

The drug, pentosan-poly-sulfoester (PPS), has an anticomplementary activity (ACA) on human serum both in vitro and in vivo, as judged by a reduction in total hemolytic complement activity (CH 50). In vitro, this ACA is very potent, immediate and temperature independent. In vivo this ACA obtained with a IV dose of 100 mg per 8 hours eg 300 mg/24 h, increases with the duration of treatment (mean time:30 days), suggesting a cumulative effect. Eleven patients with glomerulonephritis (GN) received such a treatment (8 with acute post-streptococcal GN and 3 with mesangio-proliferative GN). In patients with already marked hypocomplementemia, the ACA is difficult to establish, while in patients with normal complement activity or moderate hypocomplementemia, the decrease of CH 50 level in serum is obvious. There was no significant change inthe serum level of C3, C4, properdin factor B as measured by radial immunodiffusion technique. The clinical course of these GN was apparently not affected by this treatment. Neverthless, the in vivo ACA of PPS is firmly established and we can speculate that this functional depletion in complement may prevent or decrease the liberation of humoral mediators of inflammation.

Complement C3↗
PubMed1977

[Anticomplementary activity of a polyanion: pentosan-poly-sulfoester, II.--Mode of action and "in vitro " inhibition of human complement hemolytic activity (author's transl)].

The drug, pentosan-poly-sulfoester (PPS), is a potent in vitro inhibitor of the human complement hemolytic activity. This CH 50 inhibition represents a real anticomplementary activity (ACA), because this drug has no effect on sensitized sheep red blood cells (EA). The inhibition curve of human serum CH 50, by PPS is sigmoidal. The 50% inhibition is obtained for a 1: 650 dilution of PPS, which corresponds to a concentration of 0.08 mg/ml in normal human serum. Hemolytic titrations of C1, C4, C2, C3, and C5 showed a complete inhibition of C4, C2 and C3, and a partial inhibition of C1 (C1q, C1r, C1s, Ca++) and C5, by this drug. The mechanism of such functional inactivation of the different complement components is not yet elucidated.

Complement C2↗
PubMed1977

[Anticomplement activity of a polyanion: pentosan sulfuric polyester. III. Mechanism of functional inactivation of the different properdin and complement system fractions].

In vitro, the drug pentosan-poly-sulfoester (PPS) changes the electrophoretic migration of different proteins from the complement and properdin systems, such as native C3 (beta 1C globulin), C3c (beta-1A globulin), C3d (alpha-2D globulin), C1s inactivator (ClsINA), Clq and properdin factor B (B). Their more anodal migration is the consequence of a molecular alteration and persists after prolonged dialysis. These structural changes, yet undefined, explain the loss of functional activity of these proteins, and the anticomplementary activity of this drug. Moreover, PPS is able to block the alternate pathway activation by its action on properdin factor B (C3 proactivator). In fact, in presence of PPS, the activators of the properdin systems such as C3 nephritic factor are inactive. These altered mobilities are also responsible for the overestimation in the antigenic concentration of B (+ 45%), C4 (+27%) and C3/C3c (+ 14%), found in human serum containing 50 mg/ml of PPS. PPS has an original action upon the complement and properdin systems, which allows its clinical use as a potent inhibitor of the humoral mediators of inflammation.

Binding Sites↗
PubMed1977

Suppression of the exocrine function as an aid to of segmental pancreatic transplantation in dogs.

The injection of neoprene into the pancreatic ducts appeared to be a simple and effective means of suppression of the pancreatic exocrine function in dogs. It was investigated in experiments performed in three groups of dogs the pancreas of which were injected with 1 to 6 ml of neoprene. In group I (injection alone), all animals showed pancreatic exocrine insufficiency, none was diabetic. In group II, the dogs received a substitutive treatment and a special diet, they survived in a good general condition up to the time of sacrifice. There was extensive pancreatic fibrosis with disseminated Langerhans islets. In group III, a cephalic pancreatectomy was performed after the injection of neoprene into the pancreatic ducts, 8 animals were alive and well after 3 to 15 months, and showed a normal level of blood sugar, insulin, glucagon and amylase without glycosuria.

Amylases↗